Physician profile
Peter Pegolo
NPI 1184733255
$5,040.13
in general payments reported to CMS, 2019-2025
17 companies · $727 in 2025
The $727 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $252 · 2021: $303 · 2022: $880 · 2023: $833 · 2024: $882 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,423.27 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,459.63 | 2019-2025 | Precision7, Total30, Dailies |
| Bausch & Lomb Americas INC. | $871.06 | 2022-2025 | Miebo, Xiidra, Infuse |
| Coopervision INC. | $470.34 | 2019-2024 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $394.45 | 2019-2025 | Acuvue |
| Sight Sciences, INC. | $305.29 | 2019-2021 | |
| Allergan, INC. | $265.25 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $257.44 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $152.84 | 2019 | |
| Shire North American Group INC | $134.58 | 2019 | |
| Sun Pharmaceutical Industries INC. | $125.00 | 2019 | |
| Dompe US, INC. | $121.81 | 2023 | Oxervate |
| Menicon America INC | $121.22 | 2019-2020 | |
| Oyster Point Pharma, INC. | $111.78 | 2023 | Tyrvaya |
| Lkc Technologies, INC. | $87.72 | 2022-2023 | |
| Visioneering Technologies, INC. | $78.35 | 2019-2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $43.85 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $39.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Pegolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.